Evotec SE
EVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEvotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. The company carries a $696.2M market cap, placing it firmly in the small-cap category. It operates in two segments, Shared R&D and Just Evotec Biologics.
Market Cap
$696.2M
Beta
1.31
P/E (TTM)
—
P/E (Fwd)
-10.32
EPS (TTM)
$-0.62
EPS (Fwd)
$-0.19
ROE
-24.1%
ROA
-3.1%
Cash
$444.8M
Total Debt
$387.5M
Free CF
$98.6M
52W Change
-54.0%
Annual Financials
Cash vs Debt
With $444.8M in cash and $387.5M in debt, EVO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $98.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -24.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $751.4M (2022) to $788.4M (2025).
As with any equity investment, EVO carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing EVO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.